BOLT

Bolt Biotherapeutics, Inc. (BOLT) SWOT Analysis Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.8 (Weak)

Negative ROIC indicates capital deployment is destroying value, leaving BOLT structurally behind profitable peers that compound returns above their cost of capital.

A very negative cash conversion cycle suggests supplier financing or working-capital distortions, but peers with stable cycles typically show more predictable cash generation.

The current and quick ratios above 2.6 indicate near-term liquidity coverage, which is stronger than distressed peers but does not offset weak operating quality.

Low net debt to EBITDA implies limited leverage pressure versus more indebted peers, yet this balance-sheet cushion is secondary when returns remain deeply negative.

Weaknesses

Score:

Negative ROIC is the dominant weakness because it signals the business is not earning its cost of capital, unlike stronger peers with durable reinvestment returns.

The absence of disclosed operating and gross margins limits transparency, but peers with clear margin durability usually command better structural positioning and pricing power.

A debt-to-equity ratio above 1.7 leaves BOLT more levered than conservatively financed peers, increasing sensitivity to earnings volatility and refinancing conditions.

The extremely negative cash conversion cycle can reflect working-capital strain or accounting effects, both of which weaken comparability versus peers with cleaner cash generation.

Opportunities

Score:

If BOLT converts its liquidity cushion into operating improvement, peers with weaker balance sheets would be less able to fund turnaround investment over the next two to five years.

The low net debt to EBITDA provides optionality for restructuring or selective reinvestment, which could narrow the gap versus peers if returns normalize.

Working-capital normalization could materially improve cash generation from the current extreme cash conversion profile, creating upside relative to peers with less operating leverage.

Because current ratios are healthy, BOLT has more room than distressed peers to absorb execution setbacks while pursuing operational stabilization.

Threats

Score:

Persistent negative ROIC threatens long-term competitive relevance because peers with positive reinvestment economics can widen scale, efficiency, and customer advantages over time.

Higher leverage than many peers increases downside if operating performance stays weak, since financing costs can absorb scarce cash and constrain strategic flexibility.

If the negative cash conversion cycle reflects structural working-capital dependence, peers with cleaner cash cycles will likely sustain superior resilience through demand shocks.

Limited margin disclosure raises execution uncertainty, and peers with more transparent profitability profiles may attract capital and counterparties more easily.

Overall Score

Score:

BOLT’s structural positioning versus peers is weak because deeply negative capital returns dominate the analysis, while liquidity and leverage only partially offset the operating deficit.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Bolt Biotherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →